|Name of the Instrument/Tool||Ankylosing Spondylitis Disease Activity Score (ASDAS)|
|Concept of constructs||Disease activity|
|Originally developed for||Ankylosing spondylitis (AS)|
|Other rheumatic diseases
where can be applied (only if validated)
|Additional population with no rheumatic diseases||
|Language: Originally published in||---|
|Available in Language||English|
|Title||Assessment of SpondyloArthritis international Society. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.|
|Journal||Ann Rheum Dis.|
|Country||International Study (ASAS group)|
|Other references of interest|
Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states.
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
Extensive data about sensitivity and discriminatory ability of the ASDAS in patients treated with etanercept or sulphasalazine in the ASCEND trial.
|Instrument/Tool Translations References|
|No other References.|
|DEVELOPER CONTACT INFORMATION|
|Correspondence to||Professor Robert Landewé|
|Address||Department of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1100 DD Amsterdam|
|DESCRIPTION OF THE INSTRUMENT|
|Type Of Measure||Composite Index|
ASDAS is a composite index with continuous measurement properties. The Assessment of SpondyloArthritis international Society (ASAS) membership has selected the ASDAS containing C-reactive protein (CRP) as acute phase reactant as the preferred version, and the one with erythrocyte sedimentation rate (ESR) as the alternative version. Apart from the value of CRP or ESR, the four additional self-reported items included in this index are back pain (BASDAI question 2), duration of morning stiffness (BASDAI question 6), peripheral pain/swelling (BASDAI question 3) and patient global assessment of disease activity.
|Number of Items||5|
|Range||0 - ≈7 (arithmetically there is no upper limit)|
peripheral pain/swelling (BASDAI question 3) and patient global assessment of disease activity. Back pain and peripheral pain/swelling are anchored from 0 (none) to 10 (very severe) and patient global assessment is also anchored from 0 (not active) to 10 (very active). Duration of morning stiffness (BASDAI question 6) is anchored by a time scale (0–2 or more hours). The fifth item is the value of one of the acute phase reactants: CRP (in mg/L) or ESR (in mm/h). Items are mathematically combined to give a continuous score - the ASDAS.
|Method of administration||Self-administered|
|Recommendations to score||
The formula for ASDAS-CRP (preferred version) is:
0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.11 x Patient
The formula for ASDAS-ESR (alternative version) is:
0.08 x Back Pain + 0.07 x Duration of Morning Stiffness + 0.11 x Patient
The score is most easily calculated using an online calculator or a hand-held calculator, although it is possible to calculate longhand or using a quick ASDAS calculation form available online.
|Score Interpretation||Ranges from 0 (no disease activity) to ≈7 (maximal disease activity), although arithmetically there is no upper limit for ASDAS (upper end of the scale being determined by the level of the CRP or ESR).|
|Cut-off points||1.3 "inactive" from "low disease activity"; 2.1 "moderate" from "high disease activity"; 3.5 "high" from "very high disease activity"|
|Cut-off points applied to||Both|
|Smallest detectable change if described||0.41 to 1.06 depending on the method. "clinically important improvement" a change >=1.1 units & "major improvement" a change >=2.0 units|
|Smallest detectable change applied to||Both|
|Completion time by the patient||less than 1 minute minutes|
|Scoring time by the assessor||quick assessment forms (both available at http://www.asas-group.org/research.php?id=01) and hand-held calculator but is unwieldy without such a tool. minutes|
|Training to score||Not necessary|
|Strengths||Easy to use, Useful in clinical practice & research|
|Limitations||<5 European languages (English)|
|A. Internal Consistency||Not Tested|
|B. Reliability intraobserver or test-retest||Not Tested|
|Continuous scores: intraclass
correlation coefficient (ICC)
Dichotomus: Cohen kappa (Describe)
|C. Reliability interobserver or Measurement error||Tested|
|Standard error of measurement (SEM),
smallest detectable change (SDC) or
Limits of agreement (LoA) (Describe)
Wyrwich SEM = 0.41
SDC = 0.41 to 1.06 depending on the method
|A. Content validity: face validity||Tested|
|Expert opinion (relevance and
Items were generated by Assessment of Spondyloarthritis international Society (ASAS) members using a 3-round Delphi process. There were no patients directly involved in item generation.
Generation by an international expert group of rheumatologists (ASAS) interested in AS, and the inclusion of serologic markers of inflammation improves the face validity over solely patient-reported domains.
Extensive statistical analysis has minimized redundancy between items.
|B. Construct Validity:
Testing in a three-step statistical approach (principal component analysis, discriminant function analysis and linear regression analsyis) supports structural validity of the ASDAS.
Pearson’s correlations between the ASDAS-CRP (ASDAS-ESR) and patient global assessment was 0.72 (0.75), with physician global assessment 0.41 (0.48), with BASDAI 0.75 (0.77) and with BASFI 0.58 (0.56) in the OASIS database.
|Cross-cultural validity||Not Tested|
|C. Criterion validity||Tested|
|Comparison with a 'gold standard' Continuous scores:
correlations, ROC curves Dichotomus:
Sensitivity & Specificity (Describe)
Excellent discrimination between high and low disease activity states as defined by the physician global assessment (standardized mean difference [SMD] at baseline 1.33 for ASDAS-CRP and SMD 1.55 for ASDAS-ESR) based on the Norwegian disease-modifying anti-rheumatic drug (NORDMARD) database, and between patients treated with TNF blockers and with placebo (SMD 1.50 for ASDAS-CRP and SMD 1.51 for ASDAS-ESR) based on participants in randomized controlled trials of TNF blockers for AS.
AUC ranging from 0.74 to 0.95 against multiple gold-standards based on physician global assessment, patient global assessment and patient global rating of change after treatment.
Cut-off developed were developed using a robust methodology involving ROC curve analyses and have proven to have external validity and a good performance in cross-validation.
In RCTs with TNF-blockers versus placebo, ASDAS improvement scores perform better (higher Qui-squares) than classical improvement criteria (ASAS20, ASAS40, BASDAI50 and change in BASDAI of at least 2 units) and also that ASDAS inactive disease is more discriminative than ASAS partial remission criteria. This has implication is sample size calculation using ASDAS (lower number of patients required for the same power and α level).
|Ability to detect change over
time Multiple methods (Describe)
The ASDAS was sensitive to improvement with TNF inhibitors, with a Guyatt´s ES of 2.4 and 2.2, for ASDAS-CRP and ASDAS-ESR, respectively, compared to an ES of 1.5 for BASDAI.
|of responders with the highest/lowest
score Minimal important difference (MID) (Describe)
A change of at least 1.1 units represents “clinically important improvement” and a change of at least 2.0 units represents major improvement.
In treated patients, ASDAS and ASDAS cut-offs show a clear shift from higher towards lower disease activity states.
The ASDAS has been endorsed by the ASAS and by Outcome Measures in Rheumatology. ASDAS is emerging as the best measure of disease activity in AS/axial SpA on the basis of including both patient-generated items and objective measures of inflammation and on having, to date, equivalent or often superior psychometric performance when compared to the BASDAI.